News

Zydus Lifesciences has received the Establishment Inspection Report (EIR) and approval letter from the USFDA for the Pre-Approval Inspection (PAI) conducted at SEZ oncology injectable manufacturing site in SEZ1, Ahmedabad, in relation to the new isolator injectable line. The inspection was conducted from 4th to 13th November, 2025

Zydus Lifesciences announced that ESG Risk Assessments and Insights (ESGRAIL), a SEBI registered ESG Rating Provider has assigned overall ESG rating of 68 (last year 66) to the Company.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Dapagliflozin Tablets, 5 mg and 10 mg (USRLD: Farxiga� Tablets, 5 mg and 10 mg). Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. With this approval, Zydus is eligible for 180 days of shared generic drug exclusivity for Dapagliflozin Tablets, 5 mg and 10 mg. Dapagliflozin tablets will be manufactured at the group`s formulation manufacturing facility at SEZ, Ahmedabad. Dapagliflozin tablets had annual sales of USD 10.2bn in the United States (IQVIA MAT February 2026).

Zydus Lifesciences has launched Semaglutide Injection under the brand names � SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications. Unlike current treatment options, which often require patients to purchase multiple single-dose pens as they progressively titrate their dosage, Zydus offers an innovative reusable multi-dose novel pen device. This advancement will enable clinicians and patients to conveniently select and administer different dose strengths from a single pen, thereby improving adherence, enhancing convenience, and significantly lowering the overall therapy cost. Zydus` Semaglutide injection will be available in 15mg/3ml cartridge and will be manufactured at Zydus Biotech Park, Ahmedabad. The average monthly cost of the treatment will be approximately Rs. 2,200.Powered by Capital Market - Live News

Zydus Lifesciences has launched Aerolife Mini�, a next-generation pMDI enhancer marking a significant step in the company`s strategy to drive drug device led innovation that in respiratory care. Aerolife Mini� is India`s first portable and foldable spacer, making it highly convenient to use. Zydus has launched this device under an exclusive licensing arrangement with AeroDel Technology Innovations.Aerolife Mini� introduces a compact, foldable, and ready to use design that fundamentally redefines how spacers are used. The drug device is expected to achieve better drug deposition, improve compliance enhance patient confidence and provide greater convenience. Powered by Capital Market - Live News